More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
ACT-EARLY is testing the hypothesis that treating asymptomatic carriers of a pathogenic TTR variant with the drug acoramidis could delay amyloidosis from developing.
The Philips Azurion interventional imaging system was recently updated with new ultralow dose technology that is said to reduce X-ray exposure by up to 50% during coronary procedures.
Researchers tracked data from nearly 400 women with complex CAD who underwent treatment with Shockwave Medical's intravascular lithotripsy technology prior to PCI.
Even seeing a cardiologist once per year can help these patients elevate their long-term survival. Many stay home, however, missing out on potentially life-saving guidance and/or treatment.
Andreas Ruck, MD, discussed new registry data on Boston Scientific’s Acurate neo2 TAVR valve, comparing it to popular devices from Edwards Lifesciences and Medtronic.
